Table 3.
Demographics and transfusion information.
| Number of Patients | Percentage of Patients (%) (Total N = 201 Patients) | Number of Transfusion Events | Percentage (%) (Total N = 3426 Transfusion Events) | Average Transfusions per Person | P value | |
|---|---|---|---|---|---|---|
| Sex | 0·5164 | |||||
| Female | 86 | 42·8 | 1857 | 54·2 | 21·6 | |
| Male | 115 | 57·2 | 1569 | 45·8 | 13·6 | |
| Age | 0·0314 | |||||
| 0–10 years | 60 | 29·8 | 465 | 13·6 | 7·8 | |
| 11–18 years | 57 | 28·4 | 999 | 29·1 | 17·5 | |
| 19–25 years | 84 | 41·8 | 1962 | 57·3 | 23·4 | |
| Race/Ethnicity | 0·6084 | |||||
| Caucasian (non-Hispanic/Latino) | 74 | 36·8 | 1086 | 31·7 | 14·7 | |
| Hispanic/Latino | 66 | 32·8 | 1415 | 41·3 | 21·5 | |
| Black | 27 | 13·4 | 492 | 14·4 | 18·2 | |
| Asian | 25 | 12·5 | 204 | 5·9 | 8·2 | |
| Other/Unknown | 9 | 4·5 | 229 | 6·7 | 25·4 | |
| Underlying diagnosis | <0·0001 | |||||
| Haematopoietic cell transplant | 37 | 18·8 | 1171 | 34·2 | 31·6 | |
| Autologous | 8 | 4·0 | 255 | 7·4 | 31·9 | |
| Immune effector cell therapy | 7 | 3·5 | 76 | 2·2 | 10·9 | |
| Allogeneic | 22 | 11·0 | 840 | 24·5 | 38·2 | |
| Matched related donor | 6 | 3·0 | 120 | 3·5 | 20·0 | |
| Matched unrelated donor | 8 | 4·0 | 272 | 7·9 | 34·0 | |
| Haploidentical | 4 | 2·0 | 117 | 3·4 | 29·3 | |
| Mismatched unrelated donor | 1 | 0·5 | 23 | 0·7 | 23·0 | |
| Umbilical cord blood | 3 | 1·5 | 308 | 9·0 | 102·7 | |
| Bone marrow source | 11 | 5·5 | 325 | 9·5 | 29·5 | |
| Peripheral blood stem cells | 8 | 4·0 | 207 | 6·0 | 25·9 | |
| Myeloablative | 18 | 8·9 | 728 | 21·2 | 40·4 | |
| Reduced toxicity conditioning | 4 | 2·0 | 112 | 3·3 | 28·0 | |
| Non-haematopoietic cell transplant | 164 | 81·6 | 2255 | 65·8 | 13·8 | |
| Leukemia/lymphoma | 60 | 29·8 | 1422 | 41·5 | 24·1 | |
| Acute lymphoblastic leukemia | 35 | 17·4 | 573 | 16·7 | 16·4 | |
| Acute myeloid leukemia | 16 | 8·0 | 795 | 23·2 | 49·7 | |
| Lymphoma | 9 | 4·5 | 66 | 1·9 | 7·3 | |
| Solid tumors | 93 | 46·3 | 651 | 19·0 | 7·0 | |
| Ewing sarcoma | 14 | 7·0 | 153 | 4·5 | 10·9 | |
| Osteosarcoma | 15 | 7·5 | 132 | 3·9 | 8·8 | |
| Rhabdomyosarcoma | 14 | 7·0 | 58 | 1·7 | 4·1 | |
| Brain tumors | 16 | 8·0 | 104 | 3·0 | 6·5 | |
| Other | 34 | 16·9 | 204 | 6·0 | 6·0 | |
| Benign haematologic conditions | 11 | 5·5 | 170 | 5·0 | 15·5 | |
| Product | ||||||
| Platelets | – | – | 1726 | 50·4 | – | |
| Red blood cells | – | – | 1476 | 43·1 | – | |
| Fresh frozen plasma | – | – | 87 | 2·5 | – | |
| Cryoprecipitate | – | – | 3·3 | – | ||
| Granulocytes | – | – | 24 | 0·7 | – | |
| Premedication status | – | |||||
| Any premedication | – | – | 1789 | 52·2 | – | – |
| Premedication for fever (acetaminophen and/or hydrocortisone) | – | – | 1608 | 46·9 | – | |
| Premedication for allergic reaction (diphenhydramine and/or hydrocortisone) | – | – | 1715 | 50·1 | – | |
| Transfusion reactions reported by bedside staff | 52 | 25·9 | 93 | 2·71 | – | – |
| Transfusion reactions adjudicated by Transfusion Medicine | 45 | 22·4 | 70 | 2·04 | – | – |